Theresia M. Westers

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 78 publications

Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.

Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.

Journal: HemaSphere

Published: February 26, 2026

Toward immunoprofiling in MDS: A computational study of the bone marrow immune microenvironment.

Toward immunoprofiling in MDS: A computational study of the bone marrow immune microenvironment.

Journal: Cytometry. Part B, Clinical cytometry

Published: March 10, 2025

Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM-prognostic score (FCM-PS) for overall survival.

Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM-prognostic score (FCM-PS) for overall survival.

Journal: HemaSphere

Published: December 01, 2024

An inflammatory T-cell-stromal axis contributes to hematopoietic stem/progenitor cell failure and clonal evolution in human myelodysplastic syndrome.

An inflammatory T-cell-stromal axis contributes to hematopoietic stem/progenitor cell failure and clonal evolution in human myelodysplastic syndrome.

Journal: Nature communications

Published: November 27, 2024

Validation of the diagnostic potential of 17 immunophenotypic core markers defined by the ELN-iMDS-Flow Working Group in an independent cohort of patients with MDS.

Validation of the diagnostic potential of 17 immunophenotypic core markers defined by the ELN-iMDS-Flow Working Group in an independent cohort of patients with MDS.

Journal: HemaSphere

Published: October 14, 2024

Expression levels of genes implicated in the working mechanism of lenalidomide predict treatment response in lower risk myelodysplastic syndrome patients.

Expression levels of genes implicated in the working mechanism of lenalidomide predict treatment response in lower risk myelodysplastic syndrome patients.

Journal: Haematologica

Published: August 05, 2024

High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine.

High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine.

Journal: HemaSphere

Published: May 14, 2024

The immunoregulatory role of monocytes and thrombomodulin in myelodysplastic neoplasms.

The immunoregulatory role of monocytes and thrombomodulin in myelodysplastic neoplasms.

Journal: Frontiers in oncology

Published: April 08, 2024

The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells.

The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells.

Journal: Cytometry. Part B, Clinical cytometry

Published: March 21, 2024

Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.

Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.

Journal: HemaSphere

Published: January 31, 2024

Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells.

Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells.

Journal: Leukemia

Published: August 20, 2023

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Journal: Leukemia

Published: June 30, 2023

Showing 1-12 of 78

Last Updated: 09/26/2026